# A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)

> **NCT05293548** · PHASE2 · UNKNOWN · sponsor: **National Vaccine and Serum Institute, China** · enrollment: 516 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)
- **BIOLOGICAL:** Inactivated COVID-19 vaccine (Vero cells)

## Key facts

- **NCT ID:** NCT05293548
- **Lead sponsor:** National Vaccine and Serum Institute, China
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-25
- **Primary completion:** 2023-05
- **Final completion:** 2023-08
- **Target enrollment:** 516 (ACTUAL)
- **Last updated:** 2023-02-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05293548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05293548, "A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05293548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*